Merck's Sotatercept Study for Pulmonary Arterial Hypertension Launches in India
Merck Sharp & Dohme is conducting a study to evaluate the safety and tolerability of sotatercept in combination with standard treatments for PAH in India.
Asset / Drug
Drug and asset intelligence for Pulmonary Arterial with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.